Common TitleM97-765
Official Title Phase I/II Study of Lopinavir (ABT-378)/Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients
Phase Phase I
ClinicalTrials.gov NCT00004580
Treatments
Lopinavir-Ritonavir
Lopinavir-Ritonavir
Tradename:KaletraOther Names:LPV-RTVClass:Protease Inhibitors (PI)Categories PharmacologyTreatment-ExperiencedAdverse EffectsResistance/Virological Failure
Funding
IndustryAbbott
References
- Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
- Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75:7462-9.